Clinical study affirms efficacy of SIRT with SIR-Spheres microspheres
New clinical research has highlighted the benefits of treating metastatic colorectal cancer with SIR-SPheres microspheres.
A large multi-centre clinical study has re-affirmed that Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres is safe and effective in patients with metastatic colorectal cancer.
SIR-Spheres microspheres are fully pre-market approved by the Food and Drug Administration as a form of radiation therapy for colorectal liver metastases. They are used either alone or alongside systemic chemotherapy and are usually administered via the hepatic artery, which supplies blood to the liver.
The new studies aimed to evaluate the overall survival rates of patients and tumour response to using this type of therapy, specifically in patients who are no longer responding to chemotherapy.
Dr Andrew Kennedy, director of radiation and oncology research at the Sarah Cannon Research Institute in Nashville, Tennessee, and lead investigator, explained that patients in the study had long histories of pre-treatment. He said: "These research findings should help to further define the role of SIRT in helping to shrink or control the tumors and prolong patient survival."
The researchers reported median survival rates of 13, nine and eight months in patients who had received one, two or three prior lines of chemotherapy. There were also no significant differences in adverse affects, prompting them to conclude that SIRT with SIR-Spheres microspheres provides a "favourable risk/benefit ratio" in patients who have failed chemotherapy for metastatic colorectal cancer.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance